RUBINSTEIN JULIE sold $1.0M of ADPT

RUBINSTEIN JULIE (President and COO) sold 35,228 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $29.73 ($28.93–$31.22, $1.05M total) across 4 trades over 2026-11-11 to 2026-11-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RUBINSTEIN JULIE
Published Nov 14, 2026, 12:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The disclosed sale adds a modest bearish signal, but the small size and pre‑arranged plan limit its material impact.

02

Market read

Primary relevance is to ADPT shareholders; broader market effect is negligible.

03

What to watch

The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.

Relevance 5/10Novelty 4/10Timing: after-hours filing on 2026-11-13

Background

SEC Form 4 filing discloses an insider transaction by Adaptive Biotechnologies' President and COO.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

President and COO Julie Rubinstein sold 35,228 shares of Adaptive Biotechnologies for $1.05M via a 10b5-1 plan.

Expected impact

likely slight downward pressure as the market prices in the insider sale

Evidence & confidence

C-suite insider sales, even modest in size, are often interpreted as a bearish signal by traders.

Market effects

Minimal impact on the biotech sector; isolated to ADPT.

No regional effect beyond the company's share price.

Limited global relevance.

Counterpoint

The sale could be a routine liquidity move unrelated to company outlook.

Key entities

  • Adaptive Biotechnologies Corp

    US‑listed biotech company (ticker ADPT).

  • Julie Rubinstein

    President and COO of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.